Latest News

Varonis Systems launched Atlas, an all in one AI security solution integrated with its Data Security Platform. Atlas is designed to help enterprises with AI inventory discovery, security testing, data leak prevention, and compliance. The launch adds a new AI focused layer to Varonis Systems' existing data security offering. For investors watching NasdaqGS:VRNS, Atlas lands at a time when AI security is a central concern for many enterprise IT teams. The company’s shares most recently closed...

If you are wondering whether Wintrust Financial at US$147.91 still offers value or is starting to look stretched, the recent share price and fundamentals give you some clear clues to work with. The stock has held up over the last week with a 0.2% decline. The 30 day return sits at 8.0% and the 1 year return at 35.6%, with longer term returns of 128.2% over 3 years and 108.7% over 5 years. Recent coverage has focused on Wintrust Financial as part of broader discussions around US regional...

Why Getty Realty Stock Is Drawing Attention Now Getty Realty (GTY) has been on some investors’ radar after a stretch of positive total returns over the past year, prompting closer scrutiny of its income profile and recent share performance. See our latest analysis for Getty Realty. Getty Realty’s share price has eased slightly in the very short term, with a 1 day share price return of 0.92% decline and a 7 day share price return of 3.35% decline. However, the 90 day share price return of...

Investors in China Telecom Corporation Limited ( HKG:728 ) had a good week, as its shares rose 2.2% to close at HK$5.01...

FDA extends Priority Review for Savara’s molgramostim BLA in autoimmune PAP by three months following a major amendment. Regulator cites no new safety, efficacy, or manufacturing concerns in connection with the extension. Extension reflects ongoing review activity for Savara’s lead product candidate, ticker NasdaqGS:SVRA. Savara, listed on NasdaqGS:SVRA, focuses on therapies for rare respiratory diseases, with molgramostim as its most advanced program targeting autoimmune pulmonary alveolar...

Last week, you might have seen that InnoCare Pharma Limited ( HKG:9969 ) released its first-quarter result to the...

It looks like HRnetGroup Limited ( SGX:CHZ ) is about to go ex-dividend in the next day or two. The ex-dividend date is...

If you are wondering whether CNO Financial Group's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock most recently closed at US$43.71, with returns of 0.2% over 7 days, 7.6% over 30 days, 3.6% year to date, 12.3% over 1 year, 106.9% over 3 years and 90.8% over 5 years. This provides plenty of history to measure current pricing against. Recent coverage around CNO Financial Group has centered on its role...

Vail Resorts (NYSE:MTN) reports that an unusually warm winter and record low snowfall have sharply reduced skier visits across its resorts. The company now expects full year results to come in near the lower end of its previously issued guidance. Weather driven disruption to skier visitation is creating a material headwind for resort revenue and in resort spending. For investors watching Vail Resorts, the operational setback comes on top of a weak share price backdrop. NYSE:MTN closed at...

If you are wondering whether ANI Pharmaceuticals at around US$78.64 is priced attractively or already reflects a lot of optimism, the starting point is to understand what the current share price implies about future expectations. The stock shows mixed recent returns, with a 2.8% decline over 7 days, a 6.2% gain over 30 days, a 0.3% return year to date, 12.6% over 1 year, 108.5% over 3 years and 136.3% over 5 years. Recent coverage around ANI Pharmaceuticals has focused on its position within...

China Resources Power Holdings (SEHK:836) has released operating figures for March and the past 3 months of 2026, highlighting higher total net generation and a larger contribution from photovoltaic assets despite weaker wind conditions. See our latest analysis for China Resources Power Holdings. The recent operating update comes as the share price trades at HK$19.86, with a 7 day share price return of 5.47% and a year to date share price return of 12.65%, alongside a 5 year total shareholder...

If you are wondering whether TransMedics Group at around US$110.93 is still priced attractively or already baking in a lot of optimism, this article walks through the key valuation clues. The stock has had a mixed recent run, with a 4.3% pullback over the last 7 days, an 8.5% gain over 30 days, a 9.6% decline year to date, an 18.6% return over the past year, and a very large 3 year gain of around 40.2%. Recent headlines around TransMedics Group have continued to focus on its position in the...

Innovative Aerosystems has acquired an exclusive perpetual license from Honeywell International (NasdaqGS:HON) for aircraft power generating systems. The transaction covers customer contracts, intellectual property rights, and both OEM and aftermarket assets tied to these systems. This move reshapes how Honeywell participates in aircraft power technologies across commercial and defense programs. For you as an investor, this is a focused portfolio move within Honeywell's aerospace business...

Philip Morris International Inc. reported past first-quarter 2026 results with revenue rising to US$10.15 billion from US$9.30 billion, while net income and diluted EPS from continuing operations eased to US$2.44 billion and US$1.56 respectively, and it updated full-year 2026 EPS guidance to US$7.56–US$7.71. Beyond the headline numbers, the quarter underscored how growth in smoke-free products like IQOS and VEEV, supported by pricing power, is reshaping Philip Morris International’s earnings...

Latest FY 2026 Results Snapshot Nomura Research Institute (TSE:4307) has just capped FY 2026 with fourth quarter revenue of ¥212.4b and a basic EPS loss of ¥118.43, a sharp contrast to the trailing twelve month EPS of ¥26.62 and net income of ¥15.3b. Over the past several quarters, revenue has moved from ¥196.6b in Q4 FY 2025 to ¥195.8b, ¥201.3b and ¥205.3b, before reaching ¥212.4b in Q4 FY 2026. Quarterly basic EPS shifted from ¥38.40 to ¥45.43, ¥48.09 and ¥51.68, ahead of the latest...

Investors may be wondering whether Endeavour Mining at around $82.85 is offering good value right now, or if the easier gains are already behind it. The stock has seen a 9.1% decline over the last 7 days, a 4.1% return over 30 days, 21.8% year to date and 127.0% over the past year, which can change how investors think about both potential upside and risk. Recent coverage has focused on Endeavour Mining's position within the broader metals and mining space, including how it fits among larger...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Info-Tech...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Shimano Inc. ( TSE:7309 ) just released its first-quarter report and things are looking bullish. It was overall a...

Wondering if Axsome Therapeutics at around US$185.96 is offering fair value or stretching expectations? This breakdown will help you frame what the current price might be implying. The stock has seen a 14.9% return over the last 30 days and a 75.0% return over the last year. The year to date return sits at 4.1%, while the 7 day return is a 1.6% decline. Recent headlines around Axsome have focused on the company as a higher profile name within pharmaceuticals and biotech. This helps explain...

Fanuc (TSE:6954) closed out FY 2026 with fourth quarter revenue of ¥234.5b and basic EPS of ¥53.24, set against trailing 12 month revenue of ¥857.8b and EPS of ¥178.47. Earnings over the past year improved 12.9% with forecasts pointing to about 7.4% annual growth. Over recent periods the company has seen quarterly revenue move from ¥197.1b in FY 2025 Q3 to ¥234.5b in FY 2026 Q4, with basic EPS over those same quarters ranging from ¥35.21 to ¥53.24. Trailing net margin held at 19.4% versus...

Renesas Electronics (TSE:6723) opened Q1 2026 with revenue of ¥380.3 billion and basic EPS of ¥37.57, while trailing twelve month EPS sits at a loss of ¥5.31, underlining that the latest quarterly profit is set against a still-unprofitable year. The company has seen quarterly revenue move from ¥292.6 billion in Q4 2024 to ¥380.3 billion in Q1 2026, with basic EPS ranging from a loss of ¥33.38 in Q2 2025 to ¥58.66 in Q3 2025. Investors are watching how consistently these margins can hold up...

CIBC Capital Markets recently upgraded TC Energy to an “outperformer” rating, pointing to higher expected returns from the company’s recent energy infrastructure projects. This shift in analyst stance underlines growing confidence in how TC Energy’s new projects could reinforce the resilience of its earnings profile. With CIBC’s upgrade spotlighting improved project returns, we’ll now examine how this development may influence TC Energy’s existing investment narrative. We've uncovered the 6...